Two randomised controlled trials, recently published in the Journal of American Medicine Association (JAMA), suggest that Controlled Glucose Monitoring (CGM) greatly benefits people with type 1 diabetes (T1) who use multiple daily insulin injections (MDI), and not only the minority using insulin pumps.
The DIaMonD (Multiple Daily Injections and Continuous Glucose Monitoring in Diabetes) and GOLD studies, the first to focus solely on the benefits of CGM for adult T1s who use MDIs, were commissioned by Dexcom, and conducted in the US and Sweden respectively.
While CGM is currently used mostly by T1 patients using an insulin pump, the study results prove the system to be both beneficial and user-friendly to those on MDIs. A minority of T1 patients use an insulin pump in the UK.
Results of both trials show that Dexcom’s CGM improves HbA1c levels more than conventional treatment; the device can be used directly for making diabetes treatment decisions instead of alerting patients to use a blood glucose monitor to determine treatment.
Study findings also reveal that CGM also helps detect hypoglycaemic episodes, resulting in fewer such attacks and their inherent risks.
The Dexcom CGM system was the first produced worldwide to interact with mobile phones, and may be used with both Android and iOS smartphones, with the need for only two finger stick checks daily.
The system is available in the UK to both T1 patients and those with Type 2 diabetes who are insulin dependent.